Scientists at Sanaria and Seattle Children’s Research Institute’s Center for Global Infectious Disease Research (CGIDR) have unveiled a groundbreaking malaria vaccine, Sanaria® PfSPZ-LARC2 Vaccine, designed to provide high-level protection with just one dose.
Risk Adjusted Net Present Value: What is the current valuation of AnaptysBio’s Imsidolimab
The revenue for Imsidolimab is expected to reach an annual total of $14 mn by 2037 in the US based off GlobalData’s Expiry Model. The